Initializing Vogelview...
Performing medical cross-referencing...
Initializing Vogelview...
Performing medical cross-referencing...
Loading...
Also reported in: kU/L
Your CA 27-29 is in the normal range, consistent with no significant breast cancer-related marker production.
Your CA 27-29 level is undetectable. This is the best possible baseline result for breast cancer surveillance and monitoring.
No action needed. Continue standard breast cancer screening and follow-up.
CA 27-29 undetectable — no detectable markerYour CA 27-29 is within the normal reference range. This marker detects the same MUC1 glycoprotein as CA 15-3 and is used for similar clinical purposes. A normal result is reassuring.
No action needed. Standard breast health screening per guidelines applies.
CA 27-29 within normal reference range — no elevated breast markerYour CA 27-29 is in the low-normal range, which is a favorable baseline finding.
No action needed.
CA 27-29: low-normal — favorable baselineYour CA 27-29 is in the normal range, consistent with no significant breast cancer-related marker production.
No specific action required.
CA 27-29 within reference rangeYour CA 27-29 is in the optimal range, which is a very reassuring baseline result.
No action needed.
CA 27-29: optimal — very low marker levelYour CA 27-29 is above the reference range. This may reflect breast cancer, benign breast disease, liver disease, or other conditions. Trending the marker over time is important to assess clinical significance.
Discuss with your doctor or oncologist. Clinical breast exam and possible imaging should be arranged. Repeat testing in 4–6 weeks is advisable to assess trend.
CA 27-29 38–60 U/mL — borderline elevated; clinical correlation and monitoring requiredYour CA 27-29 is significantly elevated. At this level, the probability of active breast cancer or recurrence increases. This marker is most clinically useful for monitoring known breast cancer patients for disease progression.
Seek prompt oncology evaluation. Imaging to assess for breast cancer recurrence or metastasis is typically indicated at this level.
CA 27-29 >60 U/mL — significantly elevated; breast cancer evaluation requiredYour CA 27-29 is critically elevated, which is strongly associated with active metastatic breast cancer or significant tumor burden. Urgent re-evaluation is required.
Seek urgent specialist oncology evaluation immediately. Comprehensive re-staging and treatment planning should begin without delay.
CA 27-29 >150 U/mL — critically elevated; active metastatic breast disease likelyUpload your lab report and get your actual values interpreted in plain English — instantly, with no medical training required.